ACC 2015 | San Diego, CA | March 14-16 2015 Relation Between Frailty and Outcomes After Transcatheter Aortic Valve Replacement Philip Green, MD Columbia.

Slides:



Advertisements
Similar presentations
Impact of Anemia on One-Year Ischemic Events and Mortality Among Patients with Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention Steven.
Advertisements

Does Preoperative Hemoglobin Value Predict Postoperative Cardiovascular Complications after Total Joint Arthroplasty? Kishor Gandhi MD, MPH, Eugene Viscusi.
The mortality associated with body size and muscle mass, fat mass and abdominal obesity in patients receiving hemodialysis Date: 2012/12/21 實習生:余萍 指導老師:蕭佩珍營養師.
STS 2015 John V. Conte, MD Professor of Surgery Johns Hopkins University School of Medicine On Behalf of the CoreValve US Investigators Transcatheter Aortic.
Health-Related Quality of Life After Transcatheter vs. Surgical Aortic Valve Replacement in High-Risk Patients With Severe Aortic Stenosis Results From.
Measuring Frailty A comparison of the frailty phenotype and frailty index for the prediction of all-cause mortality James Nazroo Alan Marshall, Kris Mekli.
ACC 2015 Michael J Reardon, MD, FACC On Behalf of the CoreValve US Investigators A Randomized Comparison of Self-expanding Transcatheter and Surgical Aortic.
Frailty: its relevance to Transition Care Susan Kurrle Geriatrician, Hornsby Ku-ring-gai Health Service Curran Chair in Health Care of Older People, Faculty.
Long-Term Outcomes Using a Self- Expanding Bioprosthesis in Patients With Severe Aortic Stenosis Deemed Extreme Risk for Surgery: Two-Year Results From.
Use of Psoas Muscle Size as a Frailty Assessment Tool for Open and Transcatheter Aortic Valve Replacement Raghavendra Paknikar BS Jeffrey Friedman BS David.
Clinical Appraisal of an Article on Prognosis The Clinical Question Will the prognosis of patients with gout be affected by the administration allupurinol?
Predicting Patients at Risk for Poor Global Outcomes after DT- MCS Therapy Suzanne V. Arnold, MD, MHA Saint Luke’s Mid America Heart Institute/UMKC May.
Men, Women and Ageing Gender differences in the impact of gastrointestinal problems and their association with frailty Derrick Lopez 1, Leon Flicker 1.
Blood Pressure Lability During Cardiac Surgery Is Associated With Adverse Outcomes Solomon Aronson, Edwin G. Avery, Cornelius Dyke, Joseph Varon, Jerrold.
Complete Recovery of Renal Function After Acute Kidney Injury is Associated with Long-Term All-Cause Mortality In a Large Managed Care Organization Jennifer.
Senior Adult Oncology. Overview  Cancer is the leading cause of death for those years  60% of all cancers occur in patients who are 65 years or.
Author Disclosures Differences in Implantation-Related Adverse Events Between Men and Women Receiving ICD Therapy for Primary Prevention Differences in.
PARTNER Objective To compare surgical aortic valve replacement (AVR) with transcatheter aortic valve replacement (TAVR) in high-risk patients with severe.
The Risk and Extent of Neurological Events Are Equivalent for High-Risk Patients Treated With Transcatheter or Surgical Aortic Valve Replacement Thomas.
Prosthesis-Patient Mismatch in High Risk Patients with Severe Aortic Stenosis in a Randomized Trial of a Self-Expanding Prosthesis George L. Zorn, III.
Transcatheter Aortic-Valve Replacement with a Self-Expanding Prosthesis David H. Adams et al (U.S. CoreValve Clinical Investigators) Journal Club November.
HOPE: Heart Outcomes Prevention Evaluation study Purpose To evaluate whether the long-acting ACE inhibitor ramipril and/or vitamin E reduce the incidence.
A Novel Score to Estimate the Risk of Pneumonia After Cardiac Surgery
Bleeding in Patients Undergoing Percutaneous Coronary Interventions: A Risk Model From 302,152 Patients in the NCDR. Sameer K. Mehta MD, Andrew D. Frutkin.
TCT 2015 | San Francisco | October 15, 2015 Transcatheter Aortic Valve Replacement for Failed Surgical Bioprostheses Danny Dvir, MD John G. Webb, MD and.
TCT 2015 | San Francisco | October 15, 2015 Transcatheter Aortic Valve Replacement for Failed Surgical Bioprostheses Danny Dvir, MD John G. Webb, MD and.
The Diabetic Retinopathy Clinical Research Network Effect of Diabetes Education During Retinal Ophthalmology Visits on Diabetes Control (Protocol M) 11.
GENDER DISPARITIES AMONG PATIENTS UNDERGOING TRANSCATHETER AORTIC VALVE REPLACEMENT Michael A. Gaglia, Jr.; Michael J. Lipinski; Rebecca Torguson; Jiaxiang.
TCT 2015 | San Francisco | October 15, 2015 Howard C. Herrmann, MD on behalf of The PARTNER II Trial Investigators SAPIEN 3: Evaluation of a Balloon- Expandable.
All Rights Reserved, Duke Medicine 2008 Mechanical Dyssynchrony Defined by Phase Analysis from GSPECT: Does It Predict Mortality? Paul L. Hess, MD; Linda.
1 CONFIDENTIAL – DO NOT DISTRIBUTE ARIES mCRC: Effectiveness and Safety of 1st- and 2nd-line Bevacizumab Treatment in Elderly Patients Mark Kozloff, MD.
The Case for Rate Control: In the Management of Atrial Fibrillation Charles W. Clogston, M.D. Cardiologist CHI St. Vincent Heart Clinic Arkansas April.
DIABETES INSTITUTE JOURNAL CLUB CARINA SIGNORI, D.O., M.P.H. DECEMBER 15, 2011 Atherothrombosis intervention in metabolic syndrome with low HDL/High Triglycerides:
Ten Year Outcome of Coronary Artery Bypass Graft Surgery Versus Medical Therapy in Patients with Ischemic Cardiomyopathy Results of the Surgical Treatment.
Incidence and Outcomes of Valve Hemodynamic Deterioration in Transcatheter Aortic Valve Replacement in U.S. Clinical Practice: A Report from the Society.
Interactions Between COPD and Outcomes After Percutaneous Coronary Intervention Tomas Konecny, Krishen Somers, Marek Orban, Yuki Koshino, Ryan J. Lennon,
Longest Follow-up After Implantation of a Self-Expanding Repositionable Transcatheter Aortic Valve: Final Follow-up of the Evolut R CE Study Stephen Brecker,
The Impact of Preoperative Renal Dysfunction on the Outcomes of Patients Undergoing Transcatheter Aortic Valve Replacement Andres M. Pineda MD, J. Kevin.
Outcomes in the CoreValve US High-Risk Pivotal Trial in Patients with a Society of Thoracic Surgeons Predicted Risk of Mortality Less than or Equal to.
New Data from The PARTNER Trial
Extending the Boundaries of TAVR: Future Directions
Trans- catheter aortic valve replacement vs
Costs of Periprocedural Complications in Patients Treated with Transcatheter Aortic Valve Replacement: Results from The PARTNER Trial Suzanne V. Arnold,
Raj R. Makkar, MD On behalf of The PARTNER Trial Investigators
Are we ready to perform TAVI in Intermediate Risk Patients?
Updates From NOTION: The First All-Comer TAVR Trial
Transcatheter or Surgical Aortic Valve Replacement in Intermediate Risk Patients with Aortic Stenosis Description: The goal of the trial was to assess.
Heart Valve Thrombosis & Neuro-Outcomes
MedStar Washington Hospital Center Cardiac Catheterization Conference
TAVR in Patients with Chronic Lung Disease
Giuseppe Tarantini MD, PhD
Early Recovery of Left Ventricular Systolic Function After CoreValve Transcatheter Aortic Valve Replacement Harold L. Dauerman, MD; Michael J. Reardon,
Women, Bleeding, and Coronary Intervention
Why Radial Access Should be the Default for Women undergoing PCI?
Latest Data from Balloon Expendable Trials
Vinod H. Thourani, MD on behalf of The PARTNER Trial Investigators
Insights from the NCDR® STS/ACC TVT Registry.
CoreValve Continued Access Study Shows Continued Improvement in 1-Year Outcomes With Self-Expanding Transcatheter Aortic Valve Replacement Steven J. Yakubov,
Frailty and its association with conventional risk factors for CAD among elderly patients with acute coronary syndrome.
Ageing with ideal cardiovascular risk factors
Risk Stratification of Severe, Symptomatic Aortic Stenosis Patients
Late Follow-Up from the PARTNER Aortic Valve-in-Valve Registry
More Than Survival: Futility
Samir R. Kapadia, MD On behalf of The PARTNER Trial Investigators
Median total new lesion volume
PARTNER 2A Trial design: Intermediate-risk patients with aortic stenosis (STS PROM score 4-8%) were randomized to undergo either TAVR or SAVR, stratified.
Five-Year Outcomes after Randomization to Transcatheter or Surgical Aortic Valve Replacement: Final Results of The PARTNER 1 Trial Michael J. Mack, MD.
Applying Classification of Recommendation and Level of Evidence
Frailty and Its Effect on the 4 M’s
Transcatheter versus medical treatment of symptomatic severe tricuspid regurgitation: a propensity score matched analysis Maurizio Taramasso MD, PhD from.
Presentation transcript:

ACC 2015 | San Diego, CA | March Relation Between Frailty and Outcomes After Transcatheter Aortic Valve Replacement Philip Green, MD Columbia University on behalf of The PARTNER Trial Investigators and The PARTNER Publications Office From the PARTNER Trial

Background TAVR is a worthwhile treatment for symptomatic severe AS patients who cannot have surgery (inoperable/extreme risk) or are at high-risk for surgeryTAVR is a worthwhile treatment for symptomatic severe AS patients who cannot have surgery (inoperable/extreme risk) or are at high-risk for surgery However, after TAVR, the intermediate and long- term (thru 5 years) mortality is still high (>50%)However, after TAVR, the intermediate and long- term (thru 5 years) mortality is still high (>50%) Therefore, improving patient selection for TAVR is an important priorityTherefore, improving patient selection for TAVR is an important priority

Frailty A syndrome of impaired physiologic reserve and decreased resistance to stressors which is associated with a poor prognosis…A syndrome of impaired physiologic reserve and decreased resistance to stressors which is associated with a poor prognosis…  In the general population  In the elderly with CAD  In the elderly after general or cardiac surgery  After TAVR (small single center studies)

Physical Frailty Cardiovascular Health Study Self Reported Unintentional 10 pound weight loss Subjective exhaustion Low physical activity (survey estimated Kcal per week) Objective Measures Low grip strength Lowest 20% population BMI and gender based cut point Slow walking / gait speed Lowest 20% population Height and gender based cut point Fried LP, J Gerontol A Biol Sci Med Sci Mar;56(3):M146

Objective To evaluate the prognostic value of frailty among older adults who received TAVR in the PARTNER TrialTo evaluate the prognostic value of frailty among older adults who received TAVR in the PARTNER Trial We hypothesized that frail patients who undergo TAVR would experience:We hypothesized that frail patients who undergo TAVR would experience:  increased mortality  a higher likelihood of poor clinical outcomes

Methods All patients in PARTNER (cohorts A & B) randomized to TAVR and who received baseline frailty assessmentAll patients in PARTNER (cohorts A & B) randomized to TAVR and who received baseline frailty assessment High enrolling sites who performed objective frailty assessment prior to TAVR in consecutive patientsHigh enrolling sites who performed objective frailty assessment prior to TAVR in consecutive patients  Baylor Healthcare System, Dallas, TX (n=35)  Mayo Clinic, Rochester, MN (n=83)  Columbia University, New York, NY (n=126)

Primary Predictor Frailty Score Frailty DomainMeasureFrailty Score Slowness15 foot walk gait speed (m/s)Quartiles (0-3) WeaknessGrip strength (kg)Gender based quartiles (0-3) Wasting and malnutrition Serum albumin (g/dl)Quartiles (0-3) InactivityKatz ADLs (dress, bath, transfer, feed, toilet, continence) Any dependence=3, Independence=0 Score range = most frail 0 = least frail Green, Am Coll Cardiol Intv. 2012;5(9):974

Outcomes 1 year death from any cause Poor outcome (Arnold et al)   Considers mortality and quality of life   Success is defined as alive with acceptable or improved QOL   Poor outcome is defined as dead or with significant reduction in QOL (KCCQ reduced by 10 ~ 1 NYHA functional class) or KCCQ < 40 (class IV CHF) Arnold SV. Circ Cardiovasc Qual Outcomes Sep 1;6(5):591 Arnold SV. Circulation Jun 24;129(25):2682

Poor Outcome Arnold SV. Circ Cardiovasc Qual Outcomes Sep 1;6(5):591

Baseline Frailty Markers Non-frail (n=134) Score >= 6 Frail (n=110) Score < 6 Independent in ADLs134 (100%)38 (35%) Albumin, g/dL median (IQR)4.1 [3.8, 4.4]3.7 [3.4, 4.0] Gait speed, m/s median (IQR)0.51 [0.30, 0.76]0.27 [0.00, 0.45] Grip strength, kg (men) median (IQR)27.0 [21.3, 31.7]18.7 [13.2, 23.2] Grip strength kg (women) median (IQR)14.0 [10.9, 16.9]11.0 [9.0, 14.0]

Baseline characteristics (1) VariableNon-frail (n = 134)Frail (n = 110)p-value Age (yrs)85.4 [79.4, 89.5]87.1 [82.7, 90.3]0.11 Male gender55%47%0.22 Body mass index (kg/m2)25.8 [22.2, 29.6]24.8 [21.9, 28.3]0.46 Transfemoral TAVR46%52%0.39 STS Score (%)10.5 [8.8, 12.4]11.3 [9.6, 13.8]0.07 NYHA Class IV27%29%0.7 6-Minute Walk Test Could Not Perform17%35%0.002 Total Distance Walked (m)*192 [122, 297]146 [77, 238]

Baseline characteristics (2) VariableNon-frail (n = 134)Frail (n = 110)p-value Diabetes mellitus32%26%0.26 CAD85%83%0.62 Peripheral vascular disease 41%42%0.89 Renal disease14% 0.9 Liver disease2%8%0.03 COPD43%42%0.91 AV area (cm2)0.63 [0.50, 0.83]0.62 [0.51, 0.72]0.2 12

30 day outcomes Non-Frail (n=134)Frail (n=110)p-value Death Any cause8%10%0.49 Cardiovascular cause6%7%0.68 Repeat hospitalization*7%4%0.29 Major stroke2%1%0.68 Major bleeding5%9%0.24 Major vascular complications 5%6%0.51 Permanent pacemaker9% 0.97 Renal failure (dialysis required) 5%8%0.36 *Due to aortic stenosis or complications of the valve procedure.

Kaplan-Meier Survival Estimates Stratified by Frailty Score After adjusting for important clinical and demographic characteristics, frailty remained independently associated with… 2.5-fold increased hazard of 1-year mortality after TAVR (95% CI , p=0.002).

Poor Clinical Outcome Dead, decrease in KCCQ > 10, or KCCQ 10, or KCCQ < 40 OR 2.2 ( ) p = OR 2.4 ( ) p = 0.02

Poor Clinical Outcome Separating death and Poor QOL (KCCQ 10) 6 months months P=0.13

Markers of Frailty and Mortality at 1 year 17 VariableHR (95% CI)p-value Gait speed (m/s)*1.37 [ ]0.51 Grip strength (kg)*1.02 [ ]0.28 Albumin (g/dL)*1.25 [ ]0.21 Any ADL limitation1.59 [0.93, 2.70]0.09 Score (continuous)*1.12 [1.02, 1.22]0.01 Score (≥ 6 versus < 6)2.18 [1.27, 3.75]0.005 * Hazard ratio is per unit decrease

Limitations Secondary analysis of a subgroup from the PARTNER randomized trials Frailty composite in this analysis is a departure from well established epidemiologic definitions of frailty Very early TAVR experience with first generation device and patients at highest risk for poor outcomes No surgical or standard therapy comparisons

Conclusion Frailty as assessed by a composite of gait speed, grip strength, ADLs, and serum albumin is not associated with adverse 30-day outcomes, but is associated with increased mortality and a higher rate of poor clinical outcomes 1 year after TAVR. Frailty measurement is an essential component of the risk assessment in older adults considering therapy for AS

Thank you to the dedicated study teams at all the PARTNER Sites! Special thanks to the participants in this writing group Suzanne Arnold David J Cohen Ajay Kirtane Susheel Kodali David Brown Charanjit Rihal Ke Xu Yang Lei Marian Hawkey Rebeca Kim Maria Alu Martin Leon Michael Mack

Supplemental Material

Poor Outcome At 6-months after TAVR: occurred in 41.9% of frail participants and 27.6% of non-frail participants. – –unadjusted OR for frailty 1.89, 95% CI , p=0.04 – –After multivariable adjustment OR 2.21, 95% CI , p = 0.03 At 12 months, a poor outcome occurred in 50.0% of frail participants and 31.5% of non-frail participants – –unadjusted OR for frailty 2.17, 95% CI , p=0.02). – –After multivariable adjustment year OR 2.40, 95% CI , p = 0.02